'RevoAb™': A New Service for Antibody Developability Engineering

SENDAI, Japan- Sep 9th, 2025. RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called ***ai*Protein®** is pleased to announce the launch of a new contract research service, **'RevoAb™'**. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity.

About RevoAb™

Since December 2023, RevolKa has offered contract research services for antibody engineering using *ai*Protein®, its AI-driven protein engineering technology, through FUJIFILM Wako Pure Chemical Corporation in Japan.

RevoAb™ is a new online service for antibody developability engineering based on "RevolKa's Refined Naturalness Design concept". This refines antibody framework sequences to be close to those in naturally occurring antibodies. The pilot version was released in Japan in July 2025. Based on customer feedback, we are now launching an upgraded RevoAb™ world-wide.
With RevoAb™, users can instantly access multiple antibody sequences with potential improvement in properties, such as expression levels, stability, solubility, etc., at low prices.

For more details, please visit:
https://revoab.revolka.com/en/

Story behind RevoAb™ Development.

Antibodies are proteins that provide immune protection by recognizing and binding to substances (antigens) from infecting bacteria and viruses. They are widely used in industries, such as therapeutics and diagnostics. However, antibodies are often fragile for industrial applications, and enhancing their properties typically requires significant

time and resources.
RevolKa has successfully engineered many proteins using *ai*Protein® in collaboration with customers. For antibodies, we identified that part of *ai*Protein® could become a valuable tool for scientists struggling with suboptimal physicochemical properties. It is engineering of framework sequences of antibody by using RevolKa's Refined Naturalness Design concept. We developed RevoAb™ to provide research scientists with “Winning Antibody Sequences” instantly online.

Fees

Target	Origins	Price per target	Remarks
Fragment of variable regions (Fv)	Human Rabbit Mouse Rat	USD700	One target: one heavy chain sequence + one light chain sequence
	Others	USD350	Humanized Fv considered as human
Variable heavy domain of heavy chain (VHH)	Camelids	USD350	Humanized VHH not supported.

Registration

Please review and agree to the terms of use and privacy policy before filling out the form on the landing page.

Inquiries Regarding RevoAb™

For any question, please contact us at support-revotune@revolka.co.jp.